Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

This phase I trial investigates the effects of influenza vaccine in treating patients with stage I-IV melanoma. While intramuscular administration of influenza vaccine provides immunization against the influenza virus, giving influenza vaccine directly into the tumor (intralesional) may decrease the size of the injected melanoma tumor, or the extent of the melanoma within the body.

Trial Details

NCT ID
NCT04697576
Phase
PHASE1
Sponsor
Carlo Contreras
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Ipilimumab
  • Nivolumab
  • Pembrolizumab
  • Quadrivalent Inactivated Influenza Vaccine
  • Resection
  • Nivolumab + Relatlimab
Locations (sample)
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • Males or females
  • 18 to 99 years of age
  • Histologically confirmed cutaneous melanoma by historical pathology report review, clinical Stage I-III (Cohort #1), or Stage IV (Cohort #2) cutane…
  • At least one, biopsy-proven, palpable melanoma tumor deposit suitable for intralesional injection measuring ≥ 1 cm by digital caliper (with digital…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →